Abstract
Recordati's R&D is focused on cardiovascular diseases, anti-infectives, respiratory, anti-inflammatory, dermatology/gynaecology/urology. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.
Recordati was established in 1926 in Milan, Italy and is now listed on the Italian Stock Exchange. The company employs more than 1,900 people and its products are sold in about 100 countries.
Recordati markets products in the following fields: Cardiovascular, Central Nervous System, Gastroenterology/Urology; Respiratory and Anti-infectives. The company is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition disorders.
Current Growth Drivers
- Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, accounting for around 15 per cent of the company's total revenue. The product continues to sell well, and Recordati is investing in new combinations and formulations which should ensure future success and growth.
- Peptazol (pantoprazole), a proton pump inhibitor for the treatment of ulcers and gastro-oesophageal reflux disease, has demonstrated good year-on-year growth since its 2002 launch in the Italian market.
Key Late-Phase Products Reaching the Market Place
- Zanipress (lercanidipine+enalapril) is a new fixed combination treatment for hypertension developed by Recordati. It is currently awaiting approval in Germany, which will act as the reference member state for approval in the rest of Europe. Its launch will support the sales of Zanidip and aid Recordati in making further gains in the European hypertension market.
- Fentanyl is a centrally acting, potent analgesic which is being developed as a transdermal patch for the treatment of moderate to severe pin. Recordati has acquired rights to market this product in all the major European markets and the company hopes its launch will expand its analgesic product portfolio.
Table of Contents
Principal Operating Results
Main Therapeutic Areas
Main R&D Areas
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Key Late-Phase Products Reaching the Market Place
- Key Late-Stage Products
- Key Early-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Expenditure
- Capital Expenditure
- R&D Expenditure
- R&D Expenditure and Capital Expenditure
- Divisional Performance
- Sales By Business Area
- Sales By Business Area, 2005
- Sales to International Licensees
- Geographic Performance
- Sales By Geographic Area
- Sales By Geographic Area, 2005
- Pharmaceutical Sales By Geographical Area
- Pharmaceutical Sales By Geographical Area
- Pharmaceutical Chemicals Sales By Geographical Area
- Pharmaceutical Chemicals Sales By Geographical Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
- Product / R&D Overview
- Key Products
- R&D Strategy
- Key R&D Projects
- R&D Pipeline Overview
- Sales Forecasts
- Sales of Major Products (2000A-2010E)
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales of Major Products, 2005
- R&D Pipeline
- Cardiovascular - Products
- Major Launched Products
- Zanidip/Zanedip
- Sales
- Lercanidipine Sales by Geographic Area
- Lercanidipine Sales by Geographic Area, 2005
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents/Licensees
- Sales Forecast
- Zanidip Sales (2000A-2010E)
- Others
- Cardiovascular - R&D
- Pitavastatin
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Central Nervous System - Products
- Major Launched Products
- Elopram
- Sales
- Key Markets/Indications
- Competitor Products
- Generic Competition
- Sales Forecast
- Elopram Sales (2000A-2010E)
- Tora-dol
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Tora-dol Sales (2000A-2010E)
- Central Nervous System - R&D
- Fentanyl
- Tramadol
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Gastroenterology / Urology - Products
- Major Launched Products
- Peptazol/Ulcotenal
- Sales
- Key Markets/Indications/Formulations
- Competitor products
- Sales Forecast
- Ulcotenal Sales (2000A-2010E)
- Peptazol Sales (2000A-2010E)
- Others
- Gastroenterology / Urology - R&D
- REC 0545
- Silodosin
- Gastroenterology / Urology - Summary
- Respiratory - Products
- Exomuc and Hexa
- Sales Forecasts
- Exomuc Sales (2000A-2010E)
- Hexa Sales (2000A-2010E)
- Others
- Exomuc and Hexa
- Respiratory - R&D
- Respiratory - Summary
- Anti-infectives - Products
- Major Launched Products
- Isocef
- Sales
- Competitor Products
- Sales Forecast
- Isocef Sales (2000A-2010E)
- Octegra
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Patents
- Sales Forecast
- Octegra Sales (2000A-2010E)
- Anti-infectives - R&D
- Prulifloxacin
- Anti-infectives - Summary
- Others - Products
- Abufene
- Suplasyn
- Others - R&D
- Ciclosporin
- REC 2615
- Stanate
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- Altana
- 2nd January 2002
- Angelini
- 29th September 2004
- Asinex Ltd
- 19th October 2004
- AstraZeneca
- 26th October 1998
- July 2001
- bioMérieux-Pierre Fabre
- 11th April 2000
- 2000
- Dexcel Pharma Group
- 7th October 2002
- Eurand Pharmaceuticals Ltd
- 10th September 2004
- Forest Laboratories Inc
- 8th November 2000
- Fournier Pharma Inc
- 25th June 2001
- Grupo Uriach
- 4th September 2003
- 14th September 2004
- InfaCare Pharmaceutical Corporation
- 13th June 2005
- Kissei Pharmaceutical Co Ltd
- 13th December 2004
- Kowa Company Ltd
- 11th October 2001
- Labopharm Inc
- 16th November 2005
- Lavipharm Laboratories Inc
- 25th July 2005
- LifeCycle Pharma
- 1st April 2004
- Lundbeck
- 7th January 2002
- Meda AB
- 12th February 2002
- Napp Pharmaceuticals Ltd
- 17th June 2005
- Osmotica Pharmaceutical
- 23rd December 2005
- Roche
- Rotta Research Laboratorium SpA
- 10th November 1997
- Zambon Group
- 10th November 1997
- Licensing
- Co-Promotion/Co-Marketing
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
